Đang chuẩn bị liên kết để tải về tài liệu:
Pharmaceutical Substances Syntheses, Patents, Applications - Part 49

Pharmaceutical Substances Syntheses, Patents, Applications - Part 49. Reference containing a collection of 2267 active pharmaceutical ingredients, including those launched recently. Listed alphabetically according to their INNs and established a link between INNs, structure, synthesis and production processes, patent and literature situation, medical use, and trade names. For pharmacists and researchers | Ciprofibrate C 481 Br2 OVCH3 2 0 I ------------- bromine OH 3-bromo-4-hydroxy- 6 7-methylenedioxy-cinnoline CuCN DMF ----------------- copper l cyanide OH 3-cyono-4-hydroxy- 6 7-methylenedioxy-cinnoline n n HjC i 1. NaH DMF 2. HCI CHjCOOH ethyl iodide Referenced US 3 669 965 Eli Lilly 13.6.1972 prior. 29.12.1969 . DOS 2 005 104 Eli Lilly appl. 4.2.1970 . Formulation s cps. 250 mg 500 mg Trade Name s D Cinoxacin Rosen Pharma GB Cinobac Lilly 1979 I Cinobac Lilly Nossacin Corvi Noxigram Firma Uronorm Alfa Wassermann Uroxacin Malesci J Cinobact Shionogi USA Cinobac Dista 1981 wfm Ciprofibrate atc bo4Ac coiabos Use antihyperlipidemic clofibrate derivative RN 52214-84-3 MF CI3H14C12O3 MW 289.16 EINECS 257-744-6 CN 2- 4- 2 2-dichlorocyclopropyl phenoxy -2-methylpropanoic acid styrene 1 1 -dichloro-2-phenylcyclopropone 1. HNOj. H2S04 2. H2O 3. H2 Raney-Ni 4- 2 2 - dichlorocyclo-propyl oniline U 1. NaN02 CHjCOOH 2. H2SO4 n-------------------- 4- 2 2-dichlorocyclo-propyl phenol u h3c ch3 . I . NaOH --------k Ciprofibrote 482 C Ciprofloxacin Reference s US 3 948 973 Sterling Drug 6.4.1976 prior. 29.8.1972 . DOS 2 343 606 Sterling Drug appl. 29.8.1973 USA-prior. 29.8.1972 . synthesis o 4- 2 2-dichlorocyclopropyl aniline Nefedov O.M. Shafran R.N. Zh. Org. Khim. ZORKAE 1974 477. C.A. CHABA8 80 145626o 1974 . Formulation s cps. 100 mg tabl. 100 mg Trade Name s F Lipanor Sanofi Winthrop GB Modalim Sanofi Winthrop 1985 Ciprofloxacin Bay-o-9867 ATC J01MA02 S03AA07 Use antibacterial RN 85721-33-1 MF C17H18FN3O3 MW 331.35 LD50 122 mg kg M i.v. 5 g kg M p.o. 207 mg kg R i.v. 2 g kg R p.o. CN l-cyclopropyl-6-fluoro-l 4-dihydro-4-oxo-7- l-piperazinyl -3-quinolinecarboxylic acid monohydrate RN 113078-43-6 MF C17H18FN3O3 H2O MW 349.36 monohydrochloride RN 93107-08-5 MF C17H18FN3O3 HC1 MW 367.81 . hydrochloride RN 86483-48-9 MF C17H18FN3O3 xHCl MW unspecified LD5 I 258 mg kg M i.v. 5 g kg M p.o. 300 mg kg R i.v. 5 g kg R p.o. lactate 1 1 RN 97867-33-9 MF C17H18FN3O3 C3H O3 MW 421.43 0 1 CI